HEALTHCARE

The company is also announcing the launch of a powerful new clinical documentation improvement (CDI) product, Eleos Compliance.

Veteran Israeli venture capitalist Amir Gal-Or is launching an ambitious AI-enabled system that will produce personalized DNA-based recommendations.

The medical controversy on the matter in Israel exposes the problem of obtaining accurate clinical data on the effectiveness of medical cannabis for treating all conditions.

The Or Akiva-based medical device company is developing the Nautilus device for aneurysm treatment.

Bank of America has raised Teva's price target to $26 per share and Cantor Fitzgerald has raised Wix's price target to $260 per share.

Yaron Yakobi and Tzahi Hagag will become parties at interest in the company led by Ehud Barak and Alexander Rabinovich. ,

The Israeli pharmaceutical company's market cap gained $5 billion in one Wall Street session boosting Israeli pension funds by hundreds of millions of dollars.

Teva reported that the trial for Dukaviyug, which it is developing with Sanofi, met its endpoints in ulcerative colitis and Crohn's disease.

The winning firm is Rubinstein Ofer with Canadian architects Tye Farrow.

Remepy co-founder Michal Tsur told the Israel Business Conference about the therapy revolution whose time has come.

The Israeli pharmaceutical firm is selling its 51% stake in the joint venture to private equity firm J-Will Partners.

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

They have developed GluFormer, an AI model that can predict an individual’s future glucose levels and other health metrics based on past glucose monitoring data.

The reason for the closure is probably to do with problems at the US health insurance giant itself, which has seen its share price fall 15% in the past month.

80 medical students will be enrolled in the first four-year program, which will begin in February 2025. Annual fees are NIS 90,000.

Analysts are bullish on Teva, which is once again Israel's most valuable company, due to an improved US generics price environment and promising branded drug pipeline.

The Israeli pharmaceutical company beat the analysts and has again raised 2024 revenue guidance, this time to $16.1-16.5 billion.

The Dangoor Health-Tech Academy will foster collaboration between Israeli startups and Britain's National Health System, initially focusing on AI or automation-driven healthcare solutions.

The company has developed a device for the treatment of transcatheter tricuspid regurgitation (TR) using a revolutionary cross-caval technology.

Avraham Barak alleges that Teva's board and officers must have approved the criminal activity that led to the penalty.

Teva will pay a total of $450 million over six years to settle the cases.

The Yokneam based company has developed a nasal drug delivery system to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.

Nym has automated the entire US healthcare medical coding process to deliver a faster, more cost-effective solution that outperforms traditional manual coding.

The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.

Under the settlement, Teva's insurance company, which as far as is known is not Israeli, will pay the pharmaceutical company $40 million to fully close all potential claims.

Epitomee's product expands in the stomach, giving a sense of satiety. The big challenge now will be marketing.

The Israeli company has developed a device for the treatment of degenerative disc diseaseõ

Level Ex founder and CEO Sam Glassenberg tells "Globes" about the growing industry of medical video games and apps to train and improve the performance of doctors.

Chemomab Therapeutics is developing a treatment for rare liver scarring disease PSC.

V-Wave’s shunt is an implantable device designed to decrease elevated left atrial pressure seen in congestive heart failure.